HDM2021
/ Huadong Medicine
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 03, 2025
Discovery of HDM2021 as a Highly Potent CBL-B Inhibitor for Cancer Treatment
(SITC 2025)
- "These findings strongly support HDM2021 a novel immunomodulatory drug candidate for anti-tumor therapy. IND-enabling studies have been started for INDs application."
Hematological Malignancies • Lymphoma • Oncology • IFNG
1 to 1
Of
1
Go to page
1